Navigation Links
BioMS Medical Announces First quarter 2009 results
Date:5/11/2009

Toronto Stock Exchange Symbol: MS

EDMONTON, May 11 /PRNewswire-FirstCall/ - BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced financial and operational results for the first quarter, ended March 31, 2009.

"We remain on track to obtain the results from MAESTRO-01, the first of our two pivotal trials evaluating dirucotide in patients with secondary progressive multiple sclerosis, in the second half of 2009," said Kevin Giese, President and CEO of BioMS Medical. "We have demonstrated in previous trials that dirucotide has shown to be well tolerated and has the capacity to slow the progression of disease in certain genetically pre-disposed MS patients. If our pivotal trials confirm these results, we believe dirucotide could represent the first drug with blockbuster potential for the treatment of secondary progressive multiple sclerosis."

Currently, BioMS is conducting two pivotal clinical trials and one open-label follow-on trial of dirucotide for the treatment of secondary progressive MS (SPMS):

    -  MAESTRO-01: On January 22, 2007, BioMS announced that this pivotal
       phase III trial, being conducted in Canada and Western Europe, had
       completed full recruitment of 611 SPMS patients at 47 trial sites in
       ten countries. The primary clinical endpoint for MAESTRO-01 (and
       MAESTRO-03) is defined as a statistically and clinically significant
       increase in the time to progression of the disease as measured by the
       Expanded Disability Status Scale (EDSS), in patients with HLA-DR2
       and/or HLA-DR4 immune response genes.

       On April 21, 2009 the DSMB conducted a scheduled safety analysis and
       recommended that the trial continue to completion. To date, there have
       been ten positive safety reviews from the Data Safety Monitoring Board
       (DSMB) and this was the final scheduled review by 
'/>"/>
SOURCE BioMS Medical Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. BioMS Medical to present at Alberta Economic Forum in Geneva
2. BioMS Medical to present at BioFinance 2009
3. BioMS Medicals pivotal international multiple sclerosis trial receives positive review from Data Safety Monitoring Board
4. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
5. BioMS Medical Announces 2008 Year End Results
6. BioMS Medical warrant extension
7. BioMS Medical to present at BIO CEO and Investor Conference
8. BioMS Medical reports results of exploratory phase II trial of dirucotide in relapsing remitting multiple sclerosis
9. BioMS Medical recognized at Scrip Awards 2008
10. BioMS Medical Announces Third Quarter 2008 Results
11. BioMS Medical to present at Rodman and Renshaw Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... 2014 Women in the West ... an additional family planning option. Sayana® Press has ... all levels of the health system and in ... widely used contraceptive—Pfizer’s Depo-Provera® (depot medroxyprogesterone acetate)—with the ... the first of four African countries expected to ...
(Date:7/10/2014)... UK (PRWEB) July 10, 2014 ... 21st Century Medicine Forum on ‘Commercialising Longevity Research’ ... and entrepreneurs to the London Bioscience Innovation Center ... Research Foundation and Aging Analytics Ltd. The meeting ... investment in translational research for age-related disease, as ...
(Date:7/10/2014)... 2014 Terascala, the industry leader in ... Swahn, a former vice president of product management for ... president of marketing. Terascala’s software when combined with leading ... the highest performance and most reliable solutions for processing ... Terascala’s channel expansion and broaden its product portfolio. His ...
(Date:7/10/2014)... (PRWEB) July 10, 2014 Robert Harman, DVM, ... Medicine company, is proud to announce the relaunch of his ... with a new series called “ What are Stem Cells ... an honest and straightforward foundation in the basics of stem ... decision on the right type of treatment when considering regenerative ...
Breaking Biology Technology:Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 2Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 3Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 4Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 5Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 6DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 2DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 3DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 4DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 5DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 6Terascala Expands Executive Team 2Terascala Expands Executive Team 3Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 2Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 3
... Terrorist organizations sometimes have an advantage in the media. ... University of Haifa, published in the journal of Israel,s ... the advantage in this arena too. , ... against terrorist organizations, sometimes more so than conventional weapons. ...
... to strengthen its European business OFFENBACH MAIN, Germany, May ... Ltd., a leading multinational full service Contract Research Organization ... as President Strategic Operations Europe. Mr. Spector will be ... Mediation . Mr. Spector brings to Omega Mediation more ...
... Enfant(TM) Pediatric VEP Vision Testing System, Providing Early Detection ... If your child had vision problems, you,d be able ... Goldman, M.D., pediatrician at Children,s Health Center in Gurnee."Children ... deficits, even those they,ve had since birth," says Dr. ...
Cached Biology Technology:Information warfare in the 21st century: Ideas are sometimes stronger than bombs 2SIRO Group Appoints Scott L. Spector as President, Strategic Operations, for its European Business 2Chicago-Area Pediatricians Offering Unique Test to Detect Vision Problems in Children as Young as Six Months of Age 2
(Date:7/11/2014)... of kidney injury related to the use of hydroxyethyl ... HES molecules, according to a report in Anesthesia ... Research Society (IARS). , The "total mass of HES ... human renal proximal tubule cells (PTCs), concludes the laboratory ... Hospital Wrzburg, Austria. Other factorssuch as differences in ...
(Date:7/11/2014)... to the hippocampus, the marginal division of the ... What is the impact degree of substance P ... memory function? Yan Yu and his team, College ... using immunofluorescence staining, that substance P receptor, neurokinin ... striatal marginal division of normal rats. Unilateral or ...
(Date:7/11/2014)... Evidence exists that cannabinoid receptor type 1 ... Ca2+ influx, and reduce neurotransmitter release. However, ... 1 can increase extracellular Ca2+ influx and ... his team, Tongji Hospital Affiliated to Tongji ... Technology, China used whole cell voltage-clamp and ...
Breaking Biology News(10 mins):In lab studies, hydroxyethyl starch has direct harmful effects on kidney cells 2
... 2009 The Center for Stem Cell & Regenerative Medicine ... Clinic (CC), University Hospitals (UH), and Athersys, Inc. has ... the Research Commercialization Program. The funding will help support ... four emerging and three pilot projects. This funding will ...
... scientists from Europe and China have gathered in Barcelona this ... research projects using data from ESA and Chinese Earth observation ... and the Ministry of Science and Technology (MOST) of China ... monitor and understand environmental phenomena in China. ,The symposium, held ...
... Although every cell in the body carries the genes ... small proportion of stem cells mature into those important immune-system ... Health and his colleagues have identified two "molecular motors" that ... cells. They published their findings June 19 in the online ...
Cached Biology News:CWRU receives $5 million from Ohio Third Frontier Commission 2CWRU receives $5 million from Ohio Third Frontier Commission 3Europe and China watching Earth together 2Pushmi-pullyu of B-cell development discovered 2
...
For mRNA Differential Display with three one-base anchored oligo-dT primers and rationally designed arbitrary 13mers. These kits feature the latest generation of isotopic mRNA Differential Display t...
NATIVE, ENZYME PORCINE TRYPSIN...
G-Protein Coupled Receptor Assay, For 500 assays. SPA. Category: Drug Screening & Cellular Assays, Assays ....
Biology Products: